NEUROGENESIS INC
10QSB, EX-27, 2000-11-15
PHARMACEUTICAL PREPARATIONS
Previous: NEUROGENESIS INC, 10QSB, 2000-11-15
Next: VISION TEN INC, NT 10-Q, 2000-11-15



<TABLE> <S> <C>



<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                    3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                          78,554
<SECURITIES>                                         0
<RECEIVABLES>                                   20,984
<ALLOWANCES>                                         0
<INVENTORY>                                     23,099
<CURRENT-ASSETS>                               136,184
<PP&E>                                          17,352
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 332,996
<CURRENT-LIABILITIES>                          138,613
<BONDS>                                              0
                                0
                                          0
<COMMON>                                         1,100
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                   332,996
<SALES>                                         98,114
<TOTAL-REVENUES>                                98,114
<CGS>                                           23,499
<TOTAL-COSTS>                                   23,499
<OTHER-EXPENSES>                                64,474
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 10,140
<INCOME-TAX>                                    10,140
<INCOME-CONTINUING>                             10,140
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    10,140
<EPS-BASIC>                                     .005
<EPS-DILUTED>                                     .005



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission